National Health Service

Living With MS: ‘That Was the Week That Was’ Truly Awful

Monday Unlike Prince, my Monday wasnā€™t manic. It was barreling along quite sedately until my wife, Jane, casually noted, “Remember, youā€™ve got a dental appointment on Wednesday morning.” Er, no, I hadnā€™t remembered. It was somewhat churlish of me, as Iā€™d been waiting for this appointment for nigh on…

A Winning Belt Turns Into WrestleMania

It was a moment of clarity. Unfortunately, my attempt at making a bright, clear consommĆ© has for the moment turned into a muddled chowder! Even worse, it was writing this column that started it. Iā€™ve written so often in this column about using my Molift assistive device for transfers…

Old Friends, Broken Chairs, UTI Admissions, and Redemption

The week started with a bang, albeit with a hint of underlying anxiety. Friends and former work colleagues gathered during the first days of spring to chat in my sun-lathered back garden in South London. COVID-19 lateral flow tests had all been passed. Previously, weā€™d spent years working together on…

The Heel That Won’t Heal

The dull throbbing always hits a crescendo “in the wee small hours,” as Mr. Sinatra ā€” or rather his songwriters ā€” so aptly put it. Iā€™m referring to a wound thatā€™s been with me for over a year now. True, it disappeared for a teeny while, when my heel…

NICE Still Opposes Adding Fampyra to NHS for England

The National Institute for Health and Care Excellence (NICE) in England is set to again recommend against adding Fampyra (fampridine) to the list of medications available to multiple sclerosis (MS) patients with walking difficulties through the countryā€™s national health service (NHS). The poor cost-effectiveness of Fampyra ā€” sold…

Ponvory Now Available in Scotland at Low or No Cost Through NHS

TheĀ Scottish Medicines ConsortiumĀ (SMC)Ā has recommended thatĀ Ponvory (ponesimod) be offered through the National Health Service (NHS) Scotland to people with active, relapsing forms of multiple sclerosisĀ (MS). The decision means that the oral therapy will be available at low or no cost to patients with clinically isolated syndrome (CIS),…